It is produced by adherence and traction of the vitreous (the jelly that fills and shapes the eye) to the macula.
Symptoms: In mild cases, it may be asymptomatic. In more severe cases, it can produce metamorphopsia (lines appear distorted or curved.) The decrease of vision is variable.
Treatment: In mild cases, with good vision and low symptomatology, observation can be an option since in many cases a sudden detachment of the traction is produced. In more severe cases, with vision decrease or more important symptomatology, vitrectomy is an option. It is the removal of the vitreous jelly in order to alleviate the traction on the macula.
Alcon laboratory, Novartis division, has launched JETREA®, which is a pharmacological one-dose treatment for selected cases of VMT (vitreomacular traction.) Its active ingredient is the OCRIPLASMIN, which is administered through an intravitreal injection, that dissolves the fibers that produce the abnormal traction between the vitreous and the macula.
Tomografía de coherencia óptica (OCT, Heidelberg Engeenering) en la cual puede apreciarse la tracción que el vítreo ejerce sobre el área macular, distorsionando su arquitectura normal.